Switch to atazanavir and brachial artery reactivity (SABAR) study: endothelial function in HIV-infected subjects switched to an atazanavir regimen.

Trial Profile

Switch to atazanavir and brachial artery reactivity (SABAR) study: endothelial function in HIV-infected subjects switched to an atazanavir regimen.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Atazanavir; HIV protease inhibitors; Ritonavir
  • Indications HIV infections; Inflammation
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms SABAR
  • Most Recent Events

    • 01 Aug 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
    • 01 Jan 2010 Results published in AIDS.
    • 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top